# Black Diamond Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Black Diamond Therapeutics, Inc.](/companies/bdtx.md) (CIK 1701541)
- Form: 10-Q
- Filed: 2021-08-12
- Accepted by EDGAR: Aug 12, 2021, 08:16 ET
- Period: 2021-06-30
- Accession: 0001701541-21-000034
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000034/bdtx-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000034/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $26.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $49.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$34.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$65.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 6 months, 2021-01-01 to 2021-06-30 | $0 | us-gaap:InterestExpense |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$34.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$64.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.95 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | −$1.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.95 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | −$1.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 36,182,541 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 36,152,942 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$49.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $888.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $37.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $270.9m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $287.9m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $23.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $36.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-06-30 | $251.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1701541/000170154121000034/bdtx-20210630.htm

Filed Aug 12, 2021.
Source: SEC EDGAR, the filing index for accession 0001701541-21-000034. Last ingested by Listed: Nov 10, 2026, 16:37 ET. No prices; not investment advice.
